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WE investigated whether an interleukin 1 receptor
antagonist (IL-lra) altered cellular release of pros-
tanoids and leukotrienes in a transformed colonic
cell line (CACO-2) in the presence of proinflam-
matory stimuli. Cellular inflammation was in-
duced by treatment with lipopolysaccharide (LPS)
or the cytokine, interleukin 1 beta (IL-I). In a
separate set of experiments, cells were pretreated
with IL-lra prior to exposure to LPS or IL-I.
Prostaglandin E2 and leukotriene B4 (LTB4) levels
were quantified by ELISA assays. Both LPS and IL-
1 exposure were noted to stimulate cellular PGE2
release, a response which was significantly inhib-
ited by IL-lra treatment. Either stimulant when
administered alone failed to stimulate release of
LTB. When administered after IL-lra pretreat-
ment however, both stimuli caused a significant
increase in LTB4 release. These results suggest
that a cytokine receptor antagonist can selectively
influence eicosanoid production in this cell line.
Furthermore, this study suggests that a IL-lra may
have a future clinical role in the treatment of
inflammatory disorders of the colon which are
intimately linked to enhanced eicosanoid syn-
thesis.
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Introduction
Within the past two decades a large body of
scientific information has surfaced regarding the
molecular signals which control inflammation at
both the local and systematic levels. Many
inflammatory mediators have been recognized,
including lipid-derived substances such as ara-
chidonic acid metabolites, peptide regulatory
molecules, and certain pro-inflammatory cyto-
kines. A number of recent investigations of
inflammatory bowel disease have focused on
the role that these inflammatory mediators may
play in initiating and perpetuating disease pro-
cesses. Epithelial cells have been shown to
produce certain cytokines under specific cir-
cumstances and recent investigation has fo-
cused on the role that various humoral media-
tors of inflammation including: autacoids such
as platelet activating factor (PAF), eicosanoids,
and cytokines play in the initiation and main-
tenance of intestinal inflammatory states.1-
Cytokines are known to be important in mediat-
ing many aspects of both inflammatory and
immunologic responses, and it is likely that they
play a similar role in initiating intestinal injury
observed with inflammatory bowel disease.
Similarly, LPS is known to contribute to the
local inflammation and cellular toxicity asso-
4 ciated with Gram negative infections and is
itself known to lead to enhanced expression of
a variety of cytokines that orchestrate inflamma-
tion, immune responses,5’6 and the release of
arachidonic acid metabolites.7
IL-lra is a natural monocyte protein (22KD)
that has been cloned and expressed in recombi-
nant form.8’9 It has become a useful probe to
investigate the role of IL-I in the pathogenesis
of inflammatory disease states. The aim of the
present study was to determine the effect of IL-
lra upon cellular release of eicosanoids in
colonocytes exposed to known pro-inflamma-
tory stimuli.
Materials and Methods
A transformed colonocyte cell line CACO-2
(American Type Culture Collection, Rockville,
MD), was utilized in all experiments employing
culture techniques described previously)
Briefly, the cells were maintained in Eagle’s
minimum essential medium (MEM) supple-
mented with 20% fetal bovine serum containing
gentamicin (0.1 mg/ml) and 1% non-essential
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amino acids (Sigma, St Louis, MO). The cells
were grown in a 37C, humidified, 5% CO2
incubator, and maintained by weekly passage.
The cells were plated in six-well tissue culture
plates (Costar, Cambridge, MA) with an initial
density of 2 105 cells per well and allowed
to grow to confluence. All experiments were
conducted on cells which were 1-3 days post-
confluent. The viability of the cells was as-
sessed by trypan blue exclusion and morphol-
ogy was evaluated by routine phase contrast
microscopy.
Prior to the experiments, the cells were incu-
bated for 24 h in serum free media. At the time
of the experiments, the cells were washed
twice with Krebs-Ringer bicarbonate buffer
(KRB) and then the cells were exposed to
lipopolysaccharide (10 bg/ml; Sigma Chemical,
St Louis, MO) or IL-I (0.1 bdVl; RND Systems,
Minneapolis, MN) for 1 h. Previous studies in
our own laboratory have demonstrated signifi-
cant release of eicosanoids under such experi-
mental conditions.11’12 To evaluate the effects of
a cytokine antagonist on such eicosanoid re-
lease, IL-lra (100 btg/ml; Synergen Inc., Boulder,
CO) was dissolved in 5% sodium carbonate
solution and diluted in KRB buffer before being
added to the cells for a 1 h preincubation
period prior to subsequent exposure to LPS or
IL-113. Control wells were similarly treated with
1 ml of fresh media for a similar time period. At
the conclusion of the experiments, the media
was collected for eicosanoid determinations and
the plates frozen at -80C until quantitative
analysis of proteins was performed.
To determine protein concentrations, 0.3 ml
of 1 N sodium hydroxide was added to each
well and the wells were then thoroughly
scraped. The resultant supernatants were col-
lected and incubated in this solution for 1 h at
37C. Protein levels were then determined with
a BCA protein kit (Pierce Chemicals, Rockford,
IL) using a microtitre plate protocol and serial
dilutions of bovine serum albumin as internal
standards.13 PGE2 and leukotriene B4 (LTB4)
assays were performed in duplicate in buffer
solutions without separation by a competitive
enzyme assay which utilizes an acetylcholin-
esterase tracer (Cayman, Ann Arbor, MI). The
eicosanoid concentrations were determined by
spectrophotometric analysis of all samples after
addition of Ellman’s reagent and compared with
standard curves generated under identical con-
ditions. The data are presented as mean eico-
sanoid release (pg/mg protein) + S.E.M.
Statistical analysis was performed by analysis of
variance with a Scheffe’s post hoc test. Signifi-
cance indicates a p value < 0.05.
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Results
As indicated in Table 1, unstimulated CACO-2
cells released basal levels of PGE2 and LTB4 into
the media. Incubation of these same cells with
LPS and IL-I significantly increased the release
of PGE2, although LTB4 levels remained equiva-
lent to the basal state. Similarly, treatment of
these cells with IL-lra alone increased the basal
release of PGE2 but had no effect on LTB4
levels. Interestingly, IL-lra treatment in the
presence of LPS or IL-I reversed the note-
worthy increases in PGE2 release and led to a
paradoxical increase in cellular release of LTB4.
Discussion
The potential role that various cytokines play in
the pathogenesis of inflammatory bowel disease
has generated increased interest. In two models
of experimental colitis4,15 inflamed colonic
mucosae were found to produce and release
significantly higher amounts of IL-1 compared
with normal colonic mucosae. Increased pro-
duction of IL-1 as measured by bioassays and by
ELISA has been reported during active disease
states in both ulcerative colitis and Crohn’s
disease.16’17 In support of these observations,
Satsangi et al.
1 reported that peripheral blood
mononuclear cells obtained from patients with
active Crohn’s disease produced significantly
higher quantities of IL-1 under in vitro condi-
tions when compared with normal control
cells.
The relationship between the cytokine system
and arachidonic acid pathways is complex. A
variety of cellular and humoral mediators (i.e.
pro-inflammatory eicosanoids) may be responsi-
ble for the mucosal damage observed in colonic
inflammation. Although some cytokines are
known to directly damage cells, or to augment
the cytotoxicity of various leukocytes, some are
known to directly stimulate the synthesis of
Table 1. The effect of LPS (10 Fg/ml), IL-11 (0.1 IM) and IL-
lra (100 ig/ml) on cellular PGE2 and LTB4 release
PGE2 (pg/mg protein) LTB4 (pg/mg
protein)
Untreated 97.4 + 7.6 0.14 +/- 0.03
LPS 510.5 +/- 173.1 0.13 +/- 0.01
IL-11 612.0 + 111.3" 0.11 + 0.01
IL-lra 196.5 -t- 51.4" 0.18 -t- 0.02
LPS -t- IL-lra 114.0 + 25.1"* 0.43 +/- 0.09**
IL-11 + IL-lra 102.1 +/- 33.9- 0.41 + 0.03
Note: Each value represents the mean + S.E.M. of six values from 6
wells containing 2 10 CACO-2 cells.
*Significant from untreated cells; **significant from LPS; "signifi-
cant from IL-I.Effect ofIL-lra on colonocyte eicosanoid release
pro-inflammatory eicosanoids. Under these con-
ditions, cell membrane 1-alkyl-2-arachidonyl-1-
SN-glycerol-3-phosphocholine (G3PC) is acted
upon by phospholipase A2 to form arachidonic
acid and 1 alkyl-glycerol-phosphocholine (1
alkyl-GPC). Arachidonic acid in turn can be
converted into eicosanoids by lipoxygenase and
cyclooxygenase pathways, thus linking interleu-
kin production with the synthesis of eico-
sanoids during inflammatory states.19
Our results indicate that CACO-2 cells release
significant amounts of PGE2 in response to
stimulation with either LPS or IL-I, suggesting
that these stimulants have the capacity to
directly regulate the synthesis of prostanoids in
these cells. Since LTB4 levels were not en-
hanced under these same conditions, these data
further suggest that either the lipoxygenase arm
of the arachidonic acid cascade does not
respond in a similar manner to these same
agonists, or more likely that the noted increases
in PGE2 can exhibit an inhibitory effect on LTB4
formation in these cells. The latter concept is
supported at least in part, by the work of Ham
et al.,2 who reported that PGE2 directly inhib-
ited the release of LTB4 from activated neutro-
phils.
Our results also indicate that treatment of
CACO-2 cells with a selective IL-1 receptor
antagonist (IL-lra) induced a significant increase
in cellular release of PGE2, suggesting a similar
stimulatory effect on prostanoid synthesis in
this cell line. Although an apparent explanation
for these effects is lacking, such stimulation
could occur if the IL-lra had a direct biological
effect on the prostaglandin cascade or if it could
induce the synthesis of yet another cytokine
whose effects would be mediated through
endogenous prostaglandin synthesis. In support
of this contention is the work of Oshima et
al.,
2 who reported that in rats injected system-
ically with IL-lra, there was a significant eleva-
tion in gastric mucosal PGE2 compared with
control treated animals.
An interesting observation in the present
study was the noted effect of IL-lra pretreat-
ment upon PGE2 and LTB4 levels in cells that
were stimulated with either LPS or IL-lf3. Under
these conditions PGE2 levels were noted to
return to baseline and LTB4 levels were noted
to be significantly elevated, representing a para-
doxical shift in arachidonic acid metabolism.
Although not obvious, a potential explanation
for the observed results could be an apparent
relationship between regulatory mechanisms
governing leukotriene synthesis directly by one
or more prostaglandins which is intimately
orchestrated by IL-lra. Under these conditions,
PGE2 when available in sufficient amounts
could exert an inhibitory effect on LTB4 syn-
thesis and release. If this were the case, then
decreases in or inhibition of PGE2 synthesis
would obviate this inhibitory effect and result
in enhanced LTB4 as detected in this study. In
support of this contention are numerous studies
which demonstrate such effects in adjuvant
arthritis.22-24
Thus, there is ample evidence to implicate
various eicosanoids, and proinflammatory cyto-
kines in the pathogenesis of colitis. Although
most of the production of these mediators has
been attributed to the inflammatory cells pres-
ent in bowel wall, there is also increasing
evidence for the production of some of these
potentially proinflammatory compounds by the
mucosal epithelial cells themselves. Thus, it is
possible that epithelial cells may actually con-
tribute significantly to the pathological process
in patients with inflammatory bowel disease.
Since this process has not yet been thoroughly
delineated, further attempts to better character-
ize epithelial cell responses to initiators of
mucosal inflammation, particularly with regard
to the release of different types of prostanoids
are warranted. A better understanding of the
mechanism(s) by which the local inflammatory
process in the bowel is generalized to produce
these systemic signs and symptoms may further
suggest new therapeutic options which could
offer some palliation to these patients.
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